Langzhou Song

Summary

Affiliation: VaxInnate Corporation
Country: USA

Publications

  1. ncbi request reprint Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity
    James W Huleatt
    VaxInnate Corporation, New Haven, CT 06511, USA
    Vaccine 25:763-75. 2007
  2. pmc Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs
    Langzhou Song
    VaxInnate Corporation, Cranbury, New Jersey, United States of America
    PLoS ONE 3:e2257. 2008
  3. pmc Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin
    Langzhou Song
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512 0026, USA
    Vaccine 27:5875-84. 2009
  4. ncbi request reprint Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin
    James W Huleatt
    VaxInnate Corporation, 300 George Street, New Haven, CT 06511, USA
    Vaccine 26:201-14. 2008
  5. doi request reprint Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections
    Ge Liu
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, USA
    Vaccine 30:6833-8. 2012
  6. doi request reprint Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response
    David N Taylor
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, United States
    Vaccine 30:5761-9. 2012
  7. pmc Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice
    Ge Liu
    VaxInnate Corporation, Cranbury, New Jersey, United States of America
    PLoS ONE 6:e20928. 2011

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity
    James W Huleatt
    VaxInnate Corporation, New Haven, CT 06511, USA
    Vaccine 25:763-75. 2007
    ..Collectively our data demonstrate that PAMP:antigen fusion proteins offer significant promise for developing recombinant protein vaccines...
  2. pmc Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs
    Langzhou Song
    VaxInnate Corporation, Cranbury, New Jersey, United States of America
    PLoS ONE 3:e2257. 2008
    ..These immunologically potent vaccines can be efficiently manufactured to support pandemic response, pre-pandemic and seasonal vaccines...
  3. pmc Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin
    Langzhou Song
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512 0026, USA
    Vaccine 27:5875-84. 2009
    ..We find that replacement of domain D3 of flagellin with the VN04 HA globular head creates a highly effective vaccine that elicits protective HAI titers which protect mice against disease and death in a lethal challenge model...
  4. ncbi request reprint Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin
    James W Huleatt
    VaxInnate Corporation, 300 George Street, New Haven, CT 06511, USA
    Vaccine 26:201-14. 2008
    ..These data demonstrate that the linkage of specific TLR ligand with influenza M2e yields a vaccine candidate that offers significant promise for widespread protection against multiple influenza A virus strains...
  5. doi request reprint Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections
    Ge Liu
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, USA
    Vaccine 30:6833-8. 2012
    ..Taken together, our recombinant flagellin-HA platform has been successfully used to generate potent H5N1 HPAIV vaccine candidates. These promising preclinical results justify the advancement of these candidates into the clinic...
  6. doi request reprint Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response
    David N Taylor
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, United States
    Vaccine 30:5761-9. 2012
    ..HA1 was fused to the C-terminus of flagellin in VAX128A, replaced the D3 domain of flagellin in VAX128B and was fused in both positions in VAX128C...
  7. pmc Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice
    Ge Liu
    VaxInnate Corporation, Cranbury, New Jersey, United States of America
    PLoS ONE 6:e20928. 2011
    ..Taken together, the results demonstrate that all three vaccine candidates are highly immunogenic and efficacious in mice, and that the STF2R3.2xHA1 format is the most effective candidate vaccine format...